Cutera (NASDAQ:CUTR) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a research note released on Wednesday morning. The brokerage issued a sell rating on the medical device company’s stock.

Cutera Trading Down 3.7 %

Shares of NASDAQ:CUTR opened at $0.41 on Wednesday. The company has a 50-day moving average price of $0.41 and a 200-day moving average price of $0.68. The company has a market cap of $8.36 million, a price-to-earnings ratio of -0.06 and a beta of 1.31. Cutera has a 12 month low of $0.28 and a 12 month high of $3.10.

Cutera (NASDAQ:CUTR) last released its quarterly earnings data on Thursday, November 7th. The medical device company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.98). The business had revenue of $32.50 million during the quarter, compared to analyst estimates of $32.57 million. During the same period in the prior year, the business posted ($2.22) EPS. As a group, research analysts forecast that Cutera will post -5.78 EPS for the current fiscal year.

Institutional Trading of Cutera

An institutional investor recently raised its position in Cutera stock. Squarepoint Ops LLC increased its position in Cutera, Inc. (NASDAQ:CUTR) by 164.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 113,964 shares of the medical device company’s stock after purchasing an additional 70,870 shares during the quarter. Squarepoint Ops LLC owned approximately 0.57% of Cutera worth $172,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 90.70% of the company’s stock.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.